Audit: QRS - Jujube Red Dates for Health & Longevity
Audit conducted on 16/08/2026 06:49 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: at-a-glance vs Conclusion, protocol cells vs Therapeutic Protocol, time-to-effect vs Practical Considerations, gates vs Key Interactions & Contraindications, tiers vs Expected Benefits / Potential Risks & Side Effects, and all ten biomarker rows plus six qualitative items vs Monitoring Protocol & Defining Success. No unsupported content found. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “has never been tested in people” (line 436) mirrors the ER Conclusion; “theoretical additive sedation” (line 620) mirrors the ER interaction bullet; “(conflicted)” carries the ER’s ⚠️ Conflicted flags. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain absolute, interactions remain cautions, and both “Conflicted” markers from the ER are retained rather than dropped. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | [stop_items] draw only from the ER “Populations who should avoid Jujube Red Dates” list; [caution_items] draw only from the ER interaction bullets; no Benefit- or Risk-Modifying Factor content appears in the gates. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, citations, expert names, NCT identifiers, or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, non-promotional register throughout, matching the ER’s “a dried fruit, not a drug” framing. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Tiered benefits/risks and quantified biomarker targets sit alongside plain-language at-a-glance text. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated as noun phrases and findings, not clinical orders. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Protocol and cadence cells are descriptive noun phrases (“Split dosing preferred”, “Full panel at baseline and 12 weeks”), not directives. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No instances of “we recommend”, “you should”, or equivalent advisory framing. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns appear in any populated span. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained are those the ER itself uses as bold labels or biomarker names, required verbatim by items 4.2/4.3 and 14.2. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier items are label-plus-key-fact only; no elaborations. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address anywhere outside the fixed template disclaimer. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional-optimal biomarker targets (e.g., triglycerides < 80 mg/dL, fasting insulin 2–5 µIU/mL) address exactly this audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Split dosing, a 12-week minimum, and weekly waist/stool tracking are presented without hedging on effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Ten-marker monitoring panel and heavy-metal testing are well beyond general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The at-a-glance foregrounds the sugar cost and the baseline-dependence of the glucose effect, which is the distinction that matters for this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not appear; the only ageing reference is “slowed cellular ageing” (line 555), taken from the ER benefit heading. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terms used throughout (“alanine aminotransferase”, “immunoglobulin E-mediated allergy”, “osmotic laxative”); the plainer at-a-glance wording is required by item 7.4 and taken from the ER Conclusion. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All present and byte-identical to the template (lines 445, 490, 532, 564, 584, 635, 662, 666–668, 814). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template variable names present; marker_#_* expanded to markers 1–10 and qualitative_item_# to items 1–6, as the template intends. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | <span website="evidence_review">, <span website="audit">, and <span website="full_review"> are unchanged; a diff of lines 1–410 against the template shows no CSS or structural edits. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section that feeds the QRS is empty — every benefit tier, risk tier, gate list, protocol, monitoring, and qualitative source is populated. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | All ten [caution_items] labels and all three [action_#_label] values (“Standard protocol”, “Split versus single dosing”, “Best time of day”) match the ER bold labels verbatim; only the in-paren example-drug lists are trimmed, which item 9.5 permits. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No label is paraphrased or invented; the three time-to-effect labels name the ER’s own three time domains (lipid/glucose, bowel, waist circumference) from the single “Time to effect” bullet, which has no per-domain ER labels. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji anywhere in the file; the ER’s ⚠️ Conflicted flags are rendered as plain “(conflicted)”. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every ER section is condensed to its per-section budget: gate items are label-plus-key-fact one-liners, benefit and risk tiers are single semicolon-separated lines, and the print stylesheet with @page { size: A4 } is intact. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14; the only preceding line is <!doctype html>. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is echoed in the body other than the header date and model, which are their own spans. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly so because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: jujube_red_dates_2026-0825-0517_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0816-0637. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: jujube_red_dates_2026-0825-0517_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Jujube Red Dates for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Jujube Red Dates for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/16/2026”, matching qrs_creation_date: 2026-0816-0637. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the title and the template subline; no alternate-names line despite the ER carrying eight. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Lines 434–437 compress the Conclusion’s four load-bearing points: dried fruit not a drug, lipid and conditional glucose effect, the bowel effect as clearest, and the sugar cost. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 53 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause traces to a distinct ER Conclusion sentence (ER lines 495 and 497). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses “blood fats”, “blood sugar”, “sluggish bowel”, “concentrated sugar” — no acronyms and no clinical-register words. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial is named or referenced. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers of any kind appear. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items come from the ER “Populations who should avoid Jujube Red Dates” sub-list (ER lines 342–348). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER contraindications are present, in ER order, with none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Five <li> elements at lines 567–579. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s trailing “— absolute contraindication”, “— avoid daily long-term intake of untested fruit”, and “— absolute contraindication while the condition persists” clauses are all stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(aldolase B deficiency)”, “stage 4–5 (filtration rate below 30 mL/min/1.73 m²)”, “at or above 9%”, and “until glycaemic control is established” are all retained; only the ER’s inline gloss of eGFR is trimmed. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER contraindication bullets use no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and the ER does identify five such populations, so the emptiness rule is respected. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items map one-to-one onto the ER’s ten interaction bullets (ER lines 322–340). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Ten items, none duplicating any of the five contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Ten <li> elements at lines 587–625. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item is label plus consequence only; the ER’s “Caution./Monitor.”, mechanistic rationale, and management sentences are all dropped, and no dash clauses remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER example-drug list is retained in trimmed form (2–3 named agents each); none is dropped entirely. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER interaction bullets use plain comma-separated drug lists with no ranking notation. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and the ER identifies ten such interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells come from the ER Therapeutic Protocol bullets (ER lines 374, 382, 386). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose/duration, dosing split, and timing — the three executable decisions in the ER Protocol; the remaining bullets are alternative approaches or modifier discussion. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | Lines 449–486: all nine spans carry ER-derived content (“30 g/day dried, pitted”; “Split dosing preferred”; “Mid-morning and mid-afternoon” with matching subs). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Lipid and glucose (8–12 weeks), bowel (1–2 weeks), and waist circumference (8 weeks) — exactly the three domains in the ER “Time to effect” bullet (ER line 427). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Lipid profile is the ER’s only High-tier benefit and leads; bowel transit — the ER’s “clearest and most reproducible” effect — follows; waist circumference is last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist in the ER; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Lines 496–524: all nine spans populated; subs “Required in every trial that measured them” and “Nothing meaningful is visible at one week” are ER wording. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides explicit time-to-effect data, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All eleven benefit entries correspond to the eleven ER Expected Benefits sub-headings, in ER order and ER tier. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated (lines 534–557). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER sub-heading only; no Magnitude figures, mechanisms, or trial details carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No ER parenthetical content is preserved; the sole parenthesis, “(conflicted)”, is the emoji-free rendering of the ER’s “⚠️ Conflicted” heading flag, required by items 1.3 and 4.4. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers carry items in the ER, so no sub-section needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All nine risk entries correspond to the nine ER Potential Risks & Side Effects sub-headings, in ER order and ER tier. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated (lines 637–656). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER sub-heading only; the ER’s Magnitude figures (20–24 g sugars, 99.06%, 27.3%) are all absent. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No ER parenthetical content is preserved; the sole parenthesis, “(conflicted)”, renders the ER’s “⚠️ Conflicted” flag on reduced female fertility without the emoji. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers carry items in the ER, so no sub-section needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table rows and cadence come from the ER Monitoring Protocol & Defining Success section (ER lines 449–464). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All ten ER biomarkers present in ER order, with targets and “Why” text verbatim: triglycerides, LDL cholesterol, fasting glucose, HbA1c, fasting insulin, alanine aminotransferase, high-sensitivity C-reactive protein, waist circumference, serum ferritin, whole-blood cadmium and lead. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 805–807: baseline and 12 weeks then six-monthly, daily capillary glucose for two weeks, weekly waist and stool, annual cadmium/lead — all from the ER cadence paragraph and table notes. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items come from the ER “Qualitative markers worth tracking alongside the labs” list (ER lines 468–473). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers present verbatim and in ER order (lines 817–844). |
Issues 16/08/2026 06:49
Pass rate 100.00%. No issues found.
Issues 16/08/2026 06:43
- 4.5 — Sheet exceeds one A4 page: The Key Interactions gate reproduces all ten ER bullets with their full drug-example lists (QRS lines 586–645, ~27 rendered lines in a half-width column), which together with the 10-row Monitoring table and four-tier Benefits and Risks cards pushes the sheet well past a single A4 page.
- 11.4 — Contradictory time-to-effect sub: [time_3_sub] at QRS line 524 reads “The measure that moved fastest in trials” for Waist circumference / 8 weeks, while [time_2] on the same panel gives Bowel changes at 1–2 weeks; the phrase is lifted from the ER Monitoring table (ER line 462) where it ranks biomarkers only.
Fixes 16/08/2026 06:43
- 4.5 — Key Interactions trimmed to fit one page: Shortened the parenthetical drug-example lists in all ten [caution_items] to two or three named agents each (e.g. “metformin, glipizide, insulin” to “metformin, insulin”; “melatonin, valerian, magnesium glycinate, sour jujube seed” to “melatonin, valerian, sour jujube seed”), per 9.5, without dropping any interaction class.
- 4.5 — Monitoring cadence condensed: Tightened [monitoring_cadence] from “Full panel at baseline and at 12 weeks, then every six months while intake continues. Capillary glucose daily for the first two weeks…” to “Full panel at baseline and 12 weeks, then six-monthly. Capillary glucose daily for two weeks…”, preserving every interval.
- 11.4 — Contradictory time-to-effect sub: Changed [time_3_sub] from “The measure that moved fastest in trials” to “The fastest-moving of the measured biomarkers”, removing the contradiction with the Bowel changes cell at 1–2 weeks.